Finerenone patent expiry?

Finerenone’s patent situation depends heavily on country and which specific patent/family you mean (primary patent vs. formulation/polymorph vs. method-of-use). Patent expiry dates can also differ from regulatory exclusivity dates.

What I can give you quickly

• Global reference point: finerenone (Kerendia) was first approved in Europe in 2021 and the U.S. in 2021.
• Patent expiry is typically later than first approval, and companies often extend exclusivity via additional patent families (formulations, methods, combinations, etc.).
• A reliable answer requires specifying jurisdiction (e.g., US, EP, UK, JP) and whether you mean the latest listed “Orange Book/EP register” active patent.

To answer precisely, tell me:

1. Which country/region (US, Europe/EP, UK, Canada, Japan, etc.)?
2. Do you want earliest patent expiry or last patent expiry (most relevant for generic/biologic entry timing)?
3. Are you asking about finerenone alone or combo products?

If you reply with the jurisdiction (e.g., “US, last listed Orange Book patent”), I can look up the correct expiry target and summarize the relevant dates.